Dr. Greg Davis will be presenting on Impel's behalf at Rhinoworld 2019 in Chicago, IL on The Quantitative Scoring Scale - Nasal Mucosa (QSS-NM): A scale proposed for assessing olfactory mucosa changes following drug administration to the upper nasal space (olfactory epithelium) using a novel delivery device. For more information,...

Our CMO, Dr. Steve Shrewsbury, will be presenting the latest information on our THOR201 clinical study in Parkinson's disease at the World Parkinson's Congress in Kyoto, Japan. For more information, visit the event page here. ...

Impel NeuroPharma has developed the Precision Olfactory Delivery (POD® ) device to achieve consistent medicine delivery to the upper nasal cavity giving rapid uptake and higher bioavailability relative to standard nasal sprays. This study with dihydroergotamine mesylate (DHE) for migraine treatment compares safety, tolerability, bioavailability and pharmacokinetics (PK) of INP104...

IV DHE is effective for acute migraine. The approved label warns of potential cardiovascular effects although the clinical experience of DHE in 70 years of use has been good. Work has shown the high Cmax of IV DHE may account for a different safety profile through increased adrenergic receptor binding....

Impel NeuroPharma has developed the POD device to generate rapid, consistent systemic levels of drugs for neurological diseases. This work was to develop a L-dopa powder formulation delivered by the POD device that results in plasma exposure in rats and non-human primates (NHP), that when extrapolated to humans, will be...

The Impel team is attending the American Society of Clinical Psychopharmacology 2019 annual meeting in Scottsdale, AZ. Jasna Hocevar-Trnka, M.D., M.P.H., will be presenting a talk on the results of our SNAP101 clinical study for INP105 (acute agitation). She will be presenting Tuesday May 28 at 3:45 PM. For more...

The Impel team is attending the American Psychiatric Association 2019 annual meeting in San Francisco, CA and will be presenting data on our first clinical study for our INP105 POD-Olanzapine program. For more information, visit the event page here. ...